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aVb5 integrin was recently proposed as a coreceptor for adeno-associated virus type 2 (AAV2) infection (Summerford et
al., 1999, Nat. Med. 5, 78–82), based mainly on the direct binding of AAV2 to denatured b5 by virus overlay assay. In studies
using purified natural or recombinant human integrin aVb5 we were unable to demonstrate AAV2 binding, either by virus
overlay or by liquid binding assay. Furthermore, neither purified integrin aVb5, nor RGD peptides, nor functional blocking
monoclonal antibody blocked rAAV2 transduction. These data strongly suggest that integrin aVb5 is not involved in AAV2
infection.
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Integrins are heterodimers composed of a and b sub-
nits that specify interactions with extracellular ligands
nd mediate cell migration, cell adhesion, cell growth
nd differentiation, wound repair, and phagocytosis
Hynes, 1992; Savill et al., 1990). Integrins are also used
y a number of different viruses in order to gain entrance
o host cells (Bergelson et al., 1992; Mason et al., 1994;
oivaninen et al., 1991; Vogel et al., 1993; Wickham et al.,
993). Adenoviruses use the vitronectin-binding integrins
Vb3 and aVb5 to promote viral internalization (Bai et al.,
993; Wickham et al., 1993), rather than viral attachment
Bergelson et al., 1997), through an RGD sequence on the
enton base protein (Bai et al., 1993). Foot-and-mouth
isease virus (FMDV) also has been shown to use the
GD-binding integrin aVb3 as a receptor for viral inter-
alization (Berinstein et al., 1995). Direct interaction of
Vb5 with the adenovirus penton base protein and aVb3
ith the FMDV VP-1 G-H loop has been demonstrated by
olid-phase binding assay (Mathias et al., 1998; Jackson
t al., 1997). Viral binding and infection are EDTA sensi-
ive, can be blocked by the purified integrins and RGD-
ontaining peptides (Mathias et al., 1998; Jackson et al.,
997), and are conformationally dependent; adenovi-
uses cannot bind to denatured integrins by adenoviral
verlay assay (G. R. Nemerow, personal communication).
In recent years, AAV2, a dependovirus, has emerged
s an attractive viral vector for gene therapy, but although
AV2 vectors have shown great success in the transduc-
ion of many cell types, not all cell types can be trans-
1 To whom correspondence and reprint requests should be ad-
ressed at Hematology Branch, National Heart Lung and Blood Insti-
ute, National Institutes of Health, Building 10, Room 7C218, 9000
ockville Pike, Bethesda, MD 20892. Fax: (301) 496-8396. E-mail:biuJ@nih.gov.
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436uced by rAAV2, in part due to some cells lacking the
ost cell receptors that support initial viral binding, ab-
orption, and internalization of AAV2 (Ponnazhagan et al.,
996; Mizukami et al., 1996). Recently, heparan sulfate
roteoglycan was proposed as a receptor for AAV2
Summerford and Samulski, 1998), with aVb5 integrin
cting as a coreceptor (Summerford et al., 1999). The
vidence suggesting the role of aVb5 integrin was based
n (a) the ability of EDTA treatment of cells to decrease
AV2 infection, suggesting the possibility that an integrin
ediates infection; (b) a 100-kDa AAV2-binding protein
dentified in cell membrane fractions by virus overlay
ssay identified to be b5; and (c) cells transduced to
xpress b5 integrin showed a twofold increased suscep-
ibility to AAV2 infection. No evidence was presented to
ndicate the role of aV.
In this paper, we use both viral overlay assay and
olid-phase liquid binding assay to explore the direct
nteraction of AAV2 with integrin aVb5 and a rAAV2-LacZ
ransduction assay to look into the inhibitory effects by
ntegrin aVb5 and related molecules.
RESULTS AND DISCUSSION
Using the virus overlay assay with AAV2 we have
reviously reported the presence of a 150-kDa glycopro-
ein with a pI of 4.5–5.0 in cell membrane fractions
Mizukami et al., 1996), and using a modified sensitive
ssay we detected a second but weaker AAV2-binding
and at about 100 kDa. This 100-kDa AAV2-binding pro-
ein was identified as human nucleolin (Qiu and Brown,
999). To confirm whether the 100-kDa AAV2-binding
rotein in cell membrane fractions was integrin b5 or
uman nucleolin, a virus overlay assay was performed
sing purified natural integrin aVb5 (2 mg), copurified
uman nucleolin (4 mg), and a lectin-purified cell mem-
rane protein fraction (containing the 150-kDa AAV2-
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437INTEGRIN aVb5 AND AAV2 INFECTIONinding protein, 50 mg) as control (Fig. 1). Despite a
learly visible b5 band after Coomassie blue staining
nd b5 antibody Western blotting, there was no evidence
f AAV2 binding by viral overlay. However, as previously
eported there was a strongly AAV2-binding 150-kDa
rotein in the membrane fraction (Mizukami et al., 1996),
nd AAV2 bound to the copurified human nucleolin (Qiu
nd Brown, 1999). The lack of binding of AAV2 to the
ntegrin bands suggested that AAV2 was unable to bind
o either denatured aV or b5.
To explore the possibility that AAV2 interacted with the
Vb5 heterodimer in a manner similar to adenovirus, a
olid-phase liquid binding assay was performed in mi-
rotiter plates. Both natural integrin aVb5 and recombi-
ant aVb5 bound to adenovirus and mAb P1F6, but not to
urified AAV2 (Fig. 2), indicating that unlike adenovirus,
AV2 had no direct interaction with the aVb5 het-
rodimer.
aVb5 integrin is involved in adenovirus internalization
Wickham et al., 1993; Mathias et al., 1998), and purified
Vb5, RGD peptides, and mAb P1F6 can significantly
nhibit recombinant adenovirus gene delivery (Mathias et
l., 1998; Goldman and Wilson, 1995). We therefore used
AAV2-LacZ to identify whether rAAV2 transduction was
lso inhibited by aVb5 in a similar manner. There was no
nhibition of transduction with purified integrin aVb5 in
HO cells and HeLa cells or by RGD peptides, mAb P1F6
Fig. 3), and vitronectin, a ligand of aVb5 (data not
FIG. 1. Viral overlay and Western blotting of integrin aVb5. Protein m
ane 2), lectin-purified membrane protein (50 mg, lane 3), and purified A
as stained with Coomassie blue, or was transferred to nitrocellulose
rrow indicates the nucleolin band.hown), although in both experiments heparin reduced aAAV-LacZ transduction (Summerford and Samulski,
998).
Overall, we were unable to confirm that AAV2 binds
irectly to aVb5 integrin, either by viral overlay or by
olid-phase liquid binding assay. However, several vi-
uses are thought to use aV integrins as a receptor or
oreceptor: adenoviruses (aVb5/b3) (Wickham et al.,
r weight marker (lane 1), purified natural human integrin aVb5 (2 mg,
ith nucleolin (4 mg, lane 4) were separated by SDS–7% PAGE. The gel
rane for AAV2 viral overlay, or was Western blotted with anti-b5. The
FIG. 2. Interaction of soluble integrin aVb5 with AAV2 and adenovi-
us. Microtiter wells were coated with purified adenovirus (Ad5), AAV2,
Ab P1F6, or BSA, blocked, and washed. The wells were incubated
ith purified natural integrin aVb5 (n) or purified recombinant integrin
Vb5 (h). Integrin binding was detected with anti-b5 rabbit polyclonalolecula
AV2 w
membntibody.
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438 QIU AND BROWN993); coxsackievirus A9 (aVb3) (Roivaninen et al., 1991);
oot-and-mouth disease virus (aVb3) (Mason et al., 1994);
nd hantaviruses (aVb3) (Gavrilovskaya et al., 1998).
part from hantaviruses, in all other cases the binding
equires divalent metal cations and is EDTA sensitive,
GD peptides block both binding and infection, and
inding occurs through the RGD motif, which is pre-
ented in the capsid viral protein. However, there is no
GD sequence in the AAV2 capsid sequence (Ruffing et
l., 1994), and we were unable to inhibit transduction
sing RGD peptides, specific monoclonal antibody, or
itronectin. In addition, in contrast to the data for adeno-
irus, even at high concentration, we were unable to
nhibit transduction of rAAV2 with purified aVb5 integrin.
ogether, these data do not support a role of aVb5 in
AV2 infection.
The addition of chelating agents such as EDTA was
FIG. 3. Inhibitory effects on rAAV2 transduction. CHO cells (A) and
eLa cells (B) were grown in microtiter wells. Integrin aVb5 (1 mg/ml)
nd heparin (1 mg/ml, as control) were preincubated with rAAV-LacZ
m.o.i. 5 1.5) for 1 h and the mixture was added to cells. Alternatively,
ell monolayers were preincubated with RGD peptides (2 mg/ml), RGE
eptides (2 mg/ml, as control), mAb P1F6 (1 mg/ml), and isotype IgG1
1 mg/ml, as control) and were transduced with rAAV2-LacZ (m.o.i. 5
.5). Two days later, following transduction, b-galactosidase-positive
ells were counted by light microscopy.lso claimed to be able to block rAAV transduction (Sum- derford et al., 1999), similar to their role in blocking
denovirus infection (Svensson and Persson, 1984).
owever, recently Duan et al. (1999) reported that, in
ontrast, application of EGTA, another chelating agent, at
he time of basolateral infection with rAAV2 did not affect
ransduction and even enhanced mucosal rAAV2 trans-
uction sevenfold (Duan et al., 1998). These findings
uggest that in contrast to adenoviral infection, divalent
ations are not required for AAV2 infection, again indi-
ectly supporting our data that AAV2 and adenovirus do
ot share binding to aVb5.
At the same time that it was suggested that AAV2
inds to integrin aVb5, a separate group also proposed
asic fibroblast growth factor receptor (bFGFR) as a
oreceptor for AAV2 infection (Qing et al., 1999), similar
o that previously hypothesized for HSV infection (Kaner
t al., 1990). However, subsequent research has shown
GFR is not required in HSV infection (Muggeridge et al.,
992), and we have shown in similar studies that cell
ines lacking FGFR are still permissive for AAV2 infection
Qiu et al., 1999). Previously, our group identified a 150-
Da AAV2-binding glycoprotein in cell membrane frac-
ions of AAV2 permissive cells, absent by virus overlay
ssay in AAV2 nonpermissive cells (Mizukami et al.,
996) and present on the external surface of susceptible
ells (unpublished observations). Although this protein
emains a good candidate as a receptor for AAV2, the
dentity of this protein remains unknown. Further studies
re required on this and the other candidate receptors to
nderstand the initial events of AAV2 binding and infec-
ion.
MATERIALS AND METHODS
iruses and cells
Seed viruses (AAV2 and adenovirus type 5) and cells
KB, HeLa, and CHO-K1 cells) were purchased from the
merican Type Culture Collection (ATCC, Manassa, VA).
ll the cells were maintained as monolayers in Dul-
ecco’s modified Eagle’s minimal medium (DMEM), sup-
lemented with 10% fetal bovine serum and penicillin–
treptomycin, and maintained at 37°C in a humidified
tmosphere with 5% CO2.
irus preparations
Confluent KB cells were coinfected with AAV2 (multi-
licity of infection (m.o.i.) 5 10) and adenovirus type 5
m.o.i. 5 5), and infected cells were harvested 48 h later.
ild-type AAV2 was purified by CsCl ultracentrifugation
erformed as previously reported (Qiu and Brown, 1999)
ithout sonication treatment of the cell lysates, to pre-
ent copurification of nucleolin (Qiu and Brown, 1999).
urified AAV2 was demonstrated to be free of adenovirus
nd nucleolin by Western blotting. For adenovirus pro-
uction, KB cells were infected with adenovirus type 5
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439INTEGRIN aVb5 AND AAV2 INFECTIONm.o.i. 5 5), and 40 h postinfection cells were harvested
nd treated with 2% deoxycholate, and virus was purified
rom the soluble supernatant by two sequential rounds of
sCl ultracentrifugation. Protein concentration of the vi-
us preparations was measured by BCA protein assay
eagent (Pierce Co., Rockford, IL).
Recombinant AAV2 encoding the b-galactosidase
ene driven by the CMV promoter/enhancer sequence
rAAV2-LacZ, provided by Avigen Inc., Alameda, CA) was
roduced in an adenovirus-free system and was purified
y CsCl ultracentrifugation as previously reported (Gard-
er et al., 1997). The titer of AAV vector stock was esti-
ated to be 6.5 3 1011 genomic copies per milliliter by
outhern blot. The infectious titer of rAAV2-LacZ was
btained by infecting 293 cells with serial dilution of AAV
ector stock and determining the percentages of cells
hat were positive 48 h later. The infectious titer was
quivalent to 3.0 3 107 infectious particles per milliliter.
he AAV vector was further confirmed to be adenovirus
ree by Western blotting using a polyclonal antibody to
denovirus (Biodesign International, Kennebunk, ME).
roteins, peptides, and antibodies
Human integrin aVb5 purified protein (95% purity by
DS–PAGE) from human placenta was purchased from
hemicon International, Inc. (Temecula, CA). Soluble re-
ombinant human integrin aVb5, expressed in the bac-
lovirus system and purified using mAb P1F6 covalently
inked beads (Mathias et al., 1998), was a gift from Dr.
. R. Nemerow (Scripps Research Institute, La Jolla, CA).
ell membrane protein was prepared from a HeLa S3
embrane fraction as previously reported (Mizukami et
l., 1996), solubilized with 2% n-dodecylmatoside (DMT)
n 20 mM phosphate buffer, pH 7.2, with 1 M NaCl and
rotease inhibitor cocktail (Boehringer Mannheim,
mbH, Mannheim, Germany), and loaded on a PSA lec-
in-conjugated agarose (EY Laboratories, Inc., San Ma-
eo, CA) column. Lectin-purified protein was eluted by
00 mM methyl-a-D-glucopyranoside and 100 mM
ethyl-a-D-mannopyranoside in the same buffer as de-
cribed above with 0.1% DMT and dialyzed against 20
M Tris–HCl, pH 7.2, 1 mM EDTA, 0.05% DMT. Copurified
uman nucleolin was prepared as previously reported
Qiu and Brown, 1999). Protein concentrations for all
rotein preparations were measured by BCA protein
ssay reagent (Pierce Co.).
RGD peptide (GRGDSP) and RGE peptide (GRGESP)
ere purchased from Life Technologies Inc. (Rockville,
D). Monoclonal antibody to aVb5 integrin (P1F6, an
ntegrin functional blocking antibody), rabbit anti-aVb5
olyclonal antibody, and an IgG1 isotype control were all
rom Chemicon International Inc. Monoclonal antibody to
ntegrin b5 (B5-IVF2) was purchased from Upstate Bio-
echnology Inc. (Lake Placid, NY). Monoclonal antibody Co intact AAV2 particles (A20) was obtained from Ameri-
an Research Products Inc. (Belmont, MA).
iral overlay assay and Western blotting assay
The virus overlay protein-binding assay was per-
ormed as previously reported (Mizukami et al., 1996),
ith a slight modification. Briefly, proteins were sepa-
ated by SDS–7% PAGE and electrotransferred onto a
itrocellulose membrane. The membrane was blocked
nd incubated with purified AAV2 (20–50 mg/ml) in PBS
ith 0.1% Tween 20 and 1% BSA (PBST–BSA), after ex-
ensive washes and further incubated with monoclonal
ntibody A20 at 1:500 in PBST–BSA and horseradish
eroxidase-conjugated goat anti-mouse secondary anti-
ody (Biosource International Inc., Camarillo, CA) at
:10,000 in PBST–BSA. The detection of binding was by
hemiluminescence (Pierce Co.) and exposure to X-ray
ilm.
Western blot was performed in a similar manner, but
nstead of incubation with AAV2 and A20 monoclonal
ntibody, the transferred membrane was incubated with
onoclonal antibody.
olid-phase liquid binding assay
The assay was carried out as previously described
Mathias et al., 1998) with some modifications. Purified
AV2, adenovirus, mAb P1F6, and BSA as control were
oated onto microtiter plate wells (EIA/RIA strip plate-8,
ostar Co., Cambridge, MA) in 200 mM sodium carbon-
te buffer, pH 9.6, at 10 mg/ml, 37°C for 1 h. The plate
as blocked by PBST with 5% BSA for 1 h at RT, washed
horoughly with PBST, and incubated with either purified
Vb5 from human placenta or recombinant aVb5 at 1–2
g/ml in PBST–BSA for 1 h at RT with constant shaking.
fter washing, the strips were further incubated with a
abbit polyclonal antibody to integrin aVb5 at 1:1000 in
BST–BSA for 1 h at RT, followed by further washing. The
trips were finally incubated with a horseradish peroxi-
ase-conjugated secondary anti-rabbit antibody (Santa
ruz Biotechnology, Inc., Santa Cruz, CA) at 1:10,000 in
BST–BSA for 1 h at RT. After washing, the reaction was
eveloped by addition of ABTS solution (Boehringer
annheim GmbH, Mannheim, Germany) and absor-
ance was measured at 405 nm.
ecombinant AAV2 transduction and blocking assay
Confluent CHO cells and HeLa cells on microtiter
ells were preincubated with RGD peptides (2 mg/ml),
GE peptides (2 mg/ml), mAb P1F6 (1 mg/ml), and iso-
ype control IgG1 (1 mg/ml) in PBS at 37°C for 1 h, prior
o infection with rAAV-LacZ (m.o.i. 5 1.5). In separate
xperiments, rAAV-LacZ particles (m.o.i. 5 1.5) were pre-
ncubated in equal volume with aVb5 from human pla-
enta (1 mg/ml), heparin (1 mg/ml) in PBS with 1 mM
aCl2 and 1 mM MgCl2 for 1 h at 37°C and then added
t
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440 QIU AND BROWNo CHO cells or HeLa cells plated in microtiter wells.
fter 48 h, the monolayers were fixed with 2% glutaral-
ehyde in PBS and b-galactosidase stained (Beta-gal
taining kit, Panvera Corp., Madison, CA), and the num-
er of positive cells was counted by light microscopy.
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